Neovasc Inc. (NASDAQ: NVCN) stock bloomed in the early morning session as it jumped more than 111% to $1.65 in the pre-market session following the company’s announcement it has completed the first three Neovasc Reducer implants in France. With the implant, Neovasc continues to expand access to Reducer therapy for patients suffering from refractory angina.
Professor Martine Gilard, Director of Interventional Cardiology, and Professor Romain Didier, both of Brest University Hospital, France, conducted the implants. Prof. Stefan Verheye of the Antwerp Cardiovascular Center supported the procedure in Middelheim, Belgium. According to Prof. Gilard, “refractory angina is a burden for many French patients despite medical treatment or surgical procedures.” I’m delighted to be able to offer the Reducer treatment for the very first time in France,” he added.
An angina treatment device called the Reducer is an implant that works by altering blood flow in the heart’s myocardium and increasing the blood supply of oxygenated blood to the heart muscle’s ischemic areas. Placement of the Reducer is accomplished in approximately 20 minutes using a minimally invasive procedure.